KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查 入排置信度 0.96

Efficacy of maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed, advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial.

Philipp Harter, Marie Ange Mouret-Reynier, Sandro Pignata, Claire Cropet, Antonio González-Martín, Gerhard Bogner, Keiichi Fujiwara, Ignace Vergote, Nicoletta Colombo, Trine Jakobi Nøttrup, Anne Floquet, Ahmed El-Balat, Giovanni Scambia, Eva Maria Guerra Alia, Michel Fabbro, Barbara Schmalfeldt, Anne-Claire Hardy-Bessard, Ingo Runnebaum, Eric Pujade-Lauraine, Isabelle Ray-Coquard

Gynecol Oncol 164(2) 254-264

PMID34952708
PMCID-
DOI10.1016/j.ygyno.2021.12.016
发表日期2021-12-25
入排依据:属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
摘要

摘要

OBJECTIVES: Adding maintenance olaparib to bevacizumab provided a significant progression-free survival (PFS) benefit in patients with newly diagnosed, advanced ovarian cancer in the randomized, double-blind PAOLA-1/ENGOT-ov25 trial (NCT02477644). We analyzed PFS by clinical risk and biomarker status. METHODS: Patients received olaparib 300 mg twice daily for up to 24 months plus bevacizumab 15 mg/kg every 3 weeks for up to 15 months in total, or placebo plus bevacizumab. This post hoc exploratory analysis evaluated PFS in patients classified as higher risk (stage III with upfront surgery and residual disease or neoadjuvant chemotherapy; stage IV) or lower risk (stage III with upfront surgery and no residual disease), and by biomarker status. RESULTS: Of 806 randomized patients, 74% were higher risk and 26% were lower risk. After a median 22.9 months of follow-up, PFS favored olaparib plus bevacizumab versus placebo plus bevacizumab in higher-risk patients (hazard ratio [HR] 0.60; 95% confidence interval [CI] 0.49-0.74) and lower-risk patients (0.46; 0.30-0.72). Olaparib plus bevacizumab provided a substantial PFS benefit versus bevacizumab alone in the homologous recombination deficiency (HRD)-positive subgroup (higher risk: HR 0.39; 95% CI 0.28-0.54 and lower risk: 0.15; 0.07-0.30), with 24-month PFS rates in lower-risk patients of 90% versus 43%, respectively (Kaplan-Meier estimates). CONCLUSIONS: In PAOLA-1, maintenance olaparib plus bevacizumab provided a substantial PFS benefit in HRD-positive patients with a reduction of risk of progression or death of 61% in the higher-risk group and of 85% in the lower-risk group compared with bevacizumab alone.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。